Clorox: Finally Some Good News, But Still Behind Management's Expectations (Rating Upgrade)

Upgrading Clorox from 'sell' to 'hold' as recent financials show organic volume and revenue growth, especially in the Health and Wellness segment. Gross margin improvements and cost optimization efforts are finally materializing, though results still lag behind top peers and management expectations. The valuation is now more reasonable after a 25% stock price decline, with EV/EBITDA multiples closer to the discount CLX deserves when compared to top market players, reducing downside risk.